We want to keep you informed about the current national shortage of Beyfortus (nirsevimab), the new RSV preventative antibody medication. Supplies are limited, especially for infants weighing over 11 pounds.
Our foremost concern is the health and safety of your precious little ones. For this reason, we have made the decision to prioritize our very limited Beyfortus supply for high-risk infants, which includes preterm infants and infants under six months with chronic lung disease and those with underlying severe conditions that make them susceptible to severe RSV disease.
Please know that we are actively taking steps to prioritize patients based on their clinical needs. As more supply becomes available, we will reach out to our patient families to schedule appointments for RSV protection.
For comprehensive and detailed information regarding RSV and Beyfortus (nirsevimab), we invite you to explore our informative blog post, The New RSV Medication – What Parents Should Know.
Parents interested in joining the waitlist for Beyfortus (nirsevimab) for their child can submit a request through our website’s Contact Us section. Please be aware that due to national supply shortages, we may not be able to accommodate all waitlist requests at this time.
Your child’s health and safety continue to be our top priorities.